anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Whiplash-associated disorder comprises of a constellation of persistent symptoms after neck trauma. Tinnitus that develops postwhiplash is termed somatosensory tinnitus. The objective is to assess the role of intermediate cervical plexus block (iCPB) in patients with somatosensory tinnitus secondary to whiplash.
METHODS: Prospective service evaluation in adults with whiplash-associated disorder and concomitant somatosensory tinnitus. Patients underwent specialist otorhinolaryngology review before pain clinic referral. Patients were offered ultrasound-guided iCPB with steroids. Intensity of tinnitus was recorded on a numerical rating scale at baseline, 3 and 6 months posttreatment. Brief Pain Inventory Short Form and Hospital Anxiety Depression Scale questionnaires were also completed.
RESULTS: Over a 36-month period, 32 patients with refractory somatosensory tinnitus following whiplash were offered iCPB(s). Two patients refused because of needle phobia. iCPB(s) was performed in 30 patients as an outpatient procedure. One patient (1/30, 3.3%) was lost to follow-up. Twenty-three patients (23/30, 77%) reported clinically significant reduction in intensity of tinnitus at 3 months postprocedure. Nineteen patients (19/30, 63%) reported ongoing benefit at 6-month follow-up. Six patients failed to report any benefit (6/30, 20%).
CONCLUSION: The cervical plexus could play a significant role in the development of somatosensory tinnitus after whiplash. iCPB may have a role in the management of somatosensory tinnitus in this cohort.
PosCtrl: Positive Control Group. 2 times a day; 4 tablets / time (2 tab. of Neurotropin and 2 placebo tablets).
Patients scheduled for trapeziectomy on the basis of thumb basal joint osteoarthritis will be asked to participate. Synovial fluid from the thumb basal joint is aspirated before the joint is opened. The trapezium bone and cartilage is harvested. Blood samples to evaluated lipid profile and glucose intolerance is drawn. Blood pressure and measurements of obesity is taken. Patients are also examined at baseline and 1 year postop with grip strength, pinch strength, range of thumb motion and asked to fill in patient-rated outcome measures; QuickDASH and NRS pain.
PDS-08 is a rationally defined microbial consortium consisting of 9 strains, with FOS-inulin as prebiotic. Participants will be instructed to take 1 sachet daily for the duration of the trial.
Testosterone enanthate given as a single 100mg Intramuscular (IM) injection. Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
Neurofilament light protein (NfL) is a part of the neuronal skeleton, primarily expressed in axons, and is released when nerves are damaged. NfL has been found to be a potential diagnostic biomarker in different types of polyneuropathies. However, whether NfL levels can be used as a predictor for the risk of disease progression is currently less understood. We searched MEDLINE (PubMed), Embase, Cochrane Library, and Web of Science Searches and included longitudinal studies with a baseline and follow-up examination of adult patients with polyneuropathy and NfL measured in blood. Twenty studies investigating NfL as a predictor of disease progression were identified, examining eight polyneuropathy subtypes. The results from studies in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients were divergent, with two out of five studies finding a significant association between NfL levels and clinical outcomes. Meta-analysis of the three Guillian-Barré Syndrome (GBS) studies found higher odds for the inability to run after 1 year in patients with high levels of NfL (odds ratio 2.18, 95% confidence interval 1.04-4.56). Results from studies examining other subacute or chronic polyneuropathies like Charcot-Marie-Tooth (CMT) varied in study design and results. Our findings suggest NfL can be used as a predictor of disease progression, particularly in polyneuropathies such as CIDP and GBS. However, NfL may not serve as a reliable and cost-effective biomarker for slowly progressive polyneuropathies like CMT. Future standardized studies considering NfL as a prognostic blood biomarker in patients with different types of polyneuropathies are warranted.
Plants form two immune systems, pathogen-associated molecular pattern (PAMP)-triggered immunity (PTI) and effector-triggered immunity (ETI), to combat Blumeria graminis f. sp. tritici (Bgt) infection during the evolutionary process. In PTI, receptor-like kinases (RLKs) play important roles during pathogen infections. Based on our previous reports, there were 280 TaRLKs identified in early response to powdery mildew infection, which were divided into 34 subfamilies in this study. Differences in gene structures, cis-acting elements, and expression levels implied the function diversity of TaRLKs. TaRLK2.4, a member of LRK10L-RLKs subfamily, contained 665 amino acids, and located on the cell membrane. The main objective of this study was to investigate the role of the receptor-like kinase gene TaRLK2.4 in conferring powdery mildew resistance in wheat. Real-time quantitative PCR results indicated that TaRLK2.4 expressed during Bgt infection process, and exhibited a transgressive expression characteristic in disease resistance NILs (BJ-1). To elucidate the function of TaRLK2.4 during Bgt infection, the comprehensive analysis of virus induced gene silence and over-expression demonstrated that TaRLK2.4 promoted powdery mildew resistance positively. In summary, these results contribute to a deeper understanding of the complex and diverse biological functions of RLKs, and provide new genetic resources for wheat molecular breeding.
<P>PROBLEM TO BE SOLVED: To enable reference to up-to-date drug information at all times without special operation such as confirmation of electronic mails when referring to the up-to-date drug information.  <P>SOLUTION: An information registration means registers information related to drug information and the validity period thereof. When information related to a drug is searched for reference, a reference control means decides whether the information related to the drug is within the validity period or not, based on the information related to the validity period having been registered through the information registration means. Only when the information is valid, the reference to the drug information concerned is permitted, and the reference is inhibited when the validity period has expired. With this, it becomes possible to refer to only up-to-date drug information within the validity period.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Polyplastic glioblastoma and metastatic brain tumors are the most common brain tumors in adults. Polyplastic glioblastoma is the most common tumor among malignant primary brain tumors, and metastatic brain tumors are the most common brain tumors in adults. In the diagnosis of brain tumors, magnetic resonance imaging is the most basic and primary imaging technique to date. However, in the case of a single metastatic brain tumor, the tumor shape, signal intensity, contrast enhancement pattern, and peripheral signal intensity appear so similar that they are hardly distinguished from polymorphic glioblastoma in conventional magnetic resonance images. However, it is very important to distinguish between the two diseases because the above two diseases have completely different characteristics in clinical aspects, surgical method decisions, treatment decisions, and prognosis. Obtaining histological results will be the ultimate answer, but due to the nature of tissue called the brain, non-invasive tests are preferred, and sometimes patients (e.g., cardiovascular disease) or lesions themselves cannot handle surgery are in a very important part of the brain, so it depends on imaging techniques. In addition, the distinction between the two diseases through imaging is important in that it is important to predict in advance even if biopsy is performed through surgery. Therefore, various advanced magnetic resonance imaging techniques such as diffusion-enhanced imaging (DWI), perfusion imaging (perfusion), and spectroscopic imaging (MR spectroscopy) have been attempted to better differentiate the two diseases through imaging tests. However, these images are additional imaging tests that need to be obtained after obtaining conventional magnetic resonance images and are usually accompanied by complex and various statistical analyses due to many subjective elements. In addition, there are tests that are difficult to conduct other than large hospitals with a certain size or larger. Nevertheless, the accuracy of the discrimination between the two diseases to date is around 60%. In addition, such tests are often difficult to perform in most hospitals, except for large hospitals with a certain size or larger. Therefore, if the two diseases can be better identified in conventional magnetic resonance imaging, it will be of great help to patient care clinically and it is expected that actual clinical application will be easier. Contrast-enhanced T1 highlighted images are always performed in conventional magnetic resonance images, and after that, one more FLAIR image is obtained to see if contrast-enhanced FLAIR images are helpful in differentiating the two diseases.
The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
The square-wave bolus (for meals rich in fat and/or protein) is evenly delivered over several hours as programmed by the patient. The required insulin dose will be calculated based on patient's insulin-exchange ratio. Pure protein meal will be given 3 hours after a first breakfast.

To provide the minimal impact of the previous breakfast, all patients will receive up to 120 kcal of carbohydrates and \<100 kcal from protein and fat for the first breakfast (without any extended bolus) Patients receive a standardized pure protein meal at a second breakfast time. Meal insulin will be given as a square bolus or no meal -insulin will be given at all. The 5h post-meal glucose excursions will be recorded by self-blood glucose measurements (SMBG) (every 30 minutes) and continuous glucose monitoring system (CGMS). The intervention is taking part under in-patient clinical conditions.
Opioid use disorder (OUD) and chronic pain are commonly co-occurring disorders which can exacerbate each other. Sex/gender differences have been shown in aspects of the clinical course and biological underpinnings of both OUD and chronic pain. The purpose of this scoping review is to summarize literature which has addressed sex/gender differences in relation to the confluence of OUD and chronic pain. This review focused on peer-reviewed journal articles with human subjects and addressing (a) opioid misuse, chronic opioid use or opioid use disorder (OUD), (b) chronic or persistent pain and (c) sex/gender differences in relation to OUD and/or chronic pain. Of the 146 papers identified by the search strategy, 30 met the criteria for inclusion. Charting focused on a priori themes of chronic pain, opioid misuse/OUD and sex/gender in sample, predictor and outcome variables, and key study findings. The majority of research identified was cross-sectional in nature, and sex/gender differences and treatment effects were largely included as post-hoc analyses. Together, the results of this early work align with higher prevalence for OUD in men/males and chronic pain in women/females, while adding critical information with respect to potential sex/gender differences in the development and treatment of their co-occurrence across a range of biological and psychosocial factors. Findings underline the importance of considering sex and gender in the intersection of the development and treatment of OUD and chronic pain.
Background Effective management of hearing loss in adults is fundamental for communication, relationships, employment, and learning. This study examined the rates and management of self-reported hearing loss in urban Aboriginal and Torres Strait Islander adults. Methods A retrospective, observational study of Aboriginal and Torres Strait Islander people aged ≥15years who had annual health checks at an urban Aboriginal and Torres Strait Islander primary healthcare clinic in Inala, Queensland, was conducted to determine self-reported hearing loss rates by age and ethnic groups stratified by sex. A medical record audit of patients who self-reported hearing loss from January to June 2021 was performed to identify current management approaches, and the proportion of patients that were appropriately managed. Results Of the 1735 patients (average age 40.7years, range 15.0-88.5years, 900 [52.0%] women) who completed 3090 health checks between July 2018 and September 2021, 18.8% self-reported hearing loss. Rates did not differ between men and women. However, significant effects were noted for age, with rates increasing from 10.7% for patients aged 15-24years to 38.7% for those aged ≥65years. An audit of 73 patient medical records revealed that 39.7% of patients with self-reported hearing loss were referred to Ear, Nose and Throat/audiology or received other management. A total of 17.8% of patients owned hearing aids. Conclusions Only 40% of Aboriginal and Torres Strait Islander adults who self-reported hearing loss were referred for management. Significant changes to clinical management and government-funded referral options for hearing services are required to improve the management of self-reported hearing loss in this population.
A long-chain peptide antigen includes a plurality of epitopes. An interepitope sequence located between two of the plurality of epitopes contains four to ten consecutive tyrosines, threonines, alanines, histidines, glutamines, or asparagines. The killer T-cell recognition epitopes form complexes with MHC class I molecules and are recognized by CD8+ killer T-cells when the complexes are presented on the surfaces of antigen-presenting cells. The helper T-cell recognition epitopes form complexes with MHC class II molecules and are recognized by CD4+ helper T-cells when the complexes are presented on the surfaces of antigen-presenting cells. The peptide is cleaved within the first interepitope sequence upon uptake of the peptide into antigen-presenting cells. The long-chain peptide antigen may be administered to a patient together with a hydrophobized polysaccharide, such as cholesterol-modified pullulan, and/or an adjuvant, such as CpG oligo DNA.
This randomized controlled trial (RCT) will be conducted at Jinnah Hospital in Lahore, Pakistan, to investigate the effects of aerobic exercise with and without core muscle strengthening on pain, menstrual pattern, and quality of life in women diagnosed with endometriosis. The study will employ a convenient randomization sampling technique, aiming to recruit approximately 30 participants who meet the inclusion criteria. Eligible participants will be reproductive-age women experiencing endometriosis-related pain, with regular menstrual cycles or irregularities associated with endometriosis. They should be medically stable, cleared for physical activity, and willing to participate in an exercise intervention program. Exclusion criteria include pregnancy, severe endometriosis-related complications, significant comorbidities, recent surgery, ongoing hormonal treatments targeting endometriosis, inability to participate in exercise programs, and severe mental health conditions. By investigating these interventions, the study seeks to improve symptom management, menstrual regularity, and overall quality of life for women with endometriosis while considering safety and feasibility within the study setting.

Keywords: Endometriosis, Menstrual pattern, Aerobic Exercise, Core Muscle Strengthening, Quality of Life
Inhibiting a phosphodiesterase enzyme in a mammal comprising administration of a composition (I) comprising Morinda citrifoliafruit juice concentrate, is new. Independent claims are also included for methods for: (1) reducing allergy reactions, increase the body energy of a mammal and to reduce asthma reactions comprising administration of (I) to inhibit the action of a PDE enzyme thereby increasing the level of cyclic adenosine monophosphate (cAMP), decreasing immunoglobulin E and decreasing the secretion of histamine to decrease the allergic reaction; (2) increasing cAMP level and increasing the amount of glucose produced to increase the body energy of the mammal; and (3) increasing the level of cAMP and relaxing the muscle around the mammal's airways to decrease the severity of the reaction to asthma respectively. ACTIVITY : Antiallergic; Antiasthmatic. MECHANISM OF ACTION : Phosphodiesterases (PDEs) inhibitor. The ability of (I) to inhibit phosphodiesterases (PDE-6) was tested in Bovine retinal rod outer segments using biochemical assay. The median inhibitory concentration of (I) was 0.334%.
The invention provides traditional Chinese medicine foot bath liquid used in the remission period of coronary heart disease and angina pectoris. The traditional Chinese medicine foot bath liquid is suitable for the remission period of coronary heart disease and angina pectoris and can promote blood circulation to remove blood stasis, soften blood vessels and improve the condition of myocardial ischemia. The foot bath liquid comprises the following traditional Chinese medicines: tea root, pueraria lobata, ginkgo leaf, cassia twig, angelica sinensis, phyllanthus emblica, rhizoma zingiberis, asarum, fried pericarpium zanthoxyli, processed aconitum carmichaelii and allium macrostemon. The medicinal materials are decocted to obtain soup, and the soup is used for soaking feet. The traditional Chinese medicine foot bath liquid is used for treating the remission period of coronary heart disease and angina pectoris, the curative effect is obvious, and the satisfactory result is obtained by clinical experiments. During the treatment with medicine, no adverse reaction and no toxic or side effect are found, so that the result shows that the medication is safe and effective.
Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid.

Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally, but are usually mild and may subside with continuation of therapy. Although the absorption of iron is best when taken between meals, giving Prenatrix after meals may control occasional gastrointestinal disturbances. Prenatrix is best absorbed when taken at bedtime.

Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergic and idiosyncratic reactions are possible at lower levels. Iron, even at the usual recommended levels, has been associated with gastrointestinal intolerance in some patients.
PURPOSE:To obtain a remedy for osteoporosis, having inhibitory action on bone resorption, promoting action on bone formation and high safety, containing a benzofuro[2,3-b]quinoline derivative or a salt thereof as an active ingredient. CONSTITUTION:A benzofuro[2,3-b]quinoline derivative shown by the formula (R is H or OH) or a salt thereof is blended with a conventional drug carrier and pharmaceutically manufactured by a conventional procedure to give the aimed substance. The substance can be processed into a dosage form such as tablet, powder, capsule or injection. A dose is 10-1,000mg per adult daily in the case of oral administration and 1-100mg per adult daily in the case of parenteral administration. The compound shown by the formula is obtained by reacting m-anisidine with a phenylmalonic acid derivative, treating the reaction product with pyridine hydrochloride and dealkylating simultaneously with ring closure. 8-Hydroxy-6H-benzofuro[2,3-b]quinolin-11-one may be cited as the compound shown by the formula.
According to the present invention, spherical SDS resistant α-Syn aggregates preferentially isolate a specific synapse protein, for example, vesicle-associated membrane protein 2 (VAMP2) by direct binding. The isolation effect of the α-Syn aggregates was verified in a cell-free system, cultured primary neurons, and a PD mouse model. Also, the inventors of the present invention identified a specific blocking peptide derived from VAMP2. The peptide partially inhibited VAMP2 isolation by the α-Syn aggregates to reduce neural toxicity. These results suggest a direct mechanism of the α-Syn aggregates in neural toxicity. The blocking peptide disturbing a pathological role of the α-Syn aggregates can be used in development of potential treatment drugs for PD treatment.
BACKGROUND: Ventricular septal rupture (VSR) following acute myocardial infarction is rare in the modern revascularisation era. Nevertheless, clinical awareness is paramount, as presentation may vary.
CASE PRESENTATION: A middle-aged male with no history of cardiovascular disease developed progressive heart failure symptoms while travelling abroad. Initial workup revealed a prominent systolic murmur, but findings were inconsistent with acute coronary syndrome. Transthoracic echocardiogram showed a small hypokinetic area in the basal septum, preserved left ventricular function and no significant valvulopathy. Despite the absence of chest pain, an invasive angiography revealed occlusion of a septal branch emerging from the left anterior descending artery, otherwise patent coronary arteries. Despite administration of diuretics, the patient remained symptomatic and presented two months later to his primary care provider with a persisting systolic murmur. He was subsequently referred to the outpatient cardiology clinic where echocardiography revealed a large VSR involving the basal anteroseptum of the left ventricle with a significant left-to-right shunt. After accurate radiological and haemodynamic assessment of the defect, he successfully underwent elective surgical repair.
INTERPRETATION: Although traditionally associated with large transmural myocardial infarctions, VSR may arise also from minor, subclinical events. A new-onset murmur is a valuable hint for the alert clinician.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to ophthalmology, and can be used for treating severe forms of secondary neovascular glaucoma. Ranibizumab solution is introduced into the anterior chamber of the eye in amount of 0.025 ml (0.25 mg) with 29 G-diameter needle through a puncture within the limb parallel to the iris plane. That is followed by a contact transscleral diode laser cyclophotocoagulation (CPC) in a microimpulsive mode in a hemisphere of the eyeball in the lower hemisphere from 4 to 8 hours in 4 mm from the limb, then cyclically in upper hemisphere of eyeball from 10 to 2 hours in 4 mm from limb, with power 2,000 mW, working cycle 31.3 %, pulse duration 0.5 ms, period 1.1 ms. Exposure per one cycle makes 10 s. First cycle of exposure is performed along arc of circumference of 120 degrees in one direction, the second cycle along the same circular arc in the opposite direction; the next cycles are performed similarly to the first two cycles. Total of 8 cycles are performed in the upper hemisphere of eyeball and 8 cycles in the lower hemisphere of the eyeball. After 1 month, intravitreal introduction of VEGF inhibitor ranibizumab in amount of 0.05 ml.EFFECT: method enables achieving stable hypotensive effect and preservation of visual functions due to regression of iris neovascularization and reduced number of new vessels in ACA, reduced activity of proliferative processes in posterior segment of eye.1 cl, 2 ex